false
0001279704
0001279704
2023-11-02
2023-11-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
November 2, 2023
Cellectar Biosciences, Inc.
(Exact name of Registrant as Specified in its
Charter)
Delaware | |
1-36598 | |
04-3321804 |
(State or other jurisdiction
of incorporation) | |
(Commission
File Number) | |
(IRS Employer
Identification No.) |
100
Campus Drive, Florham Park, NJ, 07932
(Address of principal executive offices) (Zip
Code)
Registrant’s telephone number, including
area code: (608) 441-8120
N/A
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
Common Stock, par value $0.00001 per share |
|
CLRB |
|
The Nasdaq Capital
Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
Item 2.02. |
Results of Operations and Financial Condition |
On November 2, 2023, we issued a press release announcing preliminary
financial results for the three months ended September 30, 2023. A copy of the press release is furnished as Exhibit 99.1 and is
incorporated by reference herein.
Item 9.01. |
Financial Statements and Exhibits |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CELLECTAR BIOSCIENCES, INC. |
|
|
|
Date: November 2, 2023 |
By: |
/s/ Chad J. Kolean |
|
Name: |
Chad J. Kolean |
|
Title: |
Chief Financial Officer |
Exhibit 99.1
Cellectar to Release
Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024
Reports Preliminary
Financial Results for Third Quarter 2023 and Provides a Corporate Update
Conference Call scheduled
for today at 8:30 am Eastern Time
FLORHAM
PARK, N.J., Nov. 2, 2023 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical
company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that
top-line data from the pivotal trial in Waldenstrom’s macroglobulinemia (WM) will be released during the JP Morgan Healthcare conference
the week of January 8, 2024.
Third Quarter and
Recent Corporate Highlights
| · | Closed
a securities purchase agreement with certain institutional investors for a private placement
financing that, based on potential milestone payments, is expected to result in gross proceeds
of up to $102.9 million, including an initial funding of $24.5 million. The PIPE was priced
at the company’s common stock closing price on September 1, 2023, of $1.82 per
share. The financing was led by Rosalind Advisors with participation from AIGH Capital, ADAR1,
Second Line, Nantahala Capital, AuGC and other new and existing institutional investors. |
| · | Received
European Medicines Agency Priority Medicines (PRIME) Designation for iopofosine I 131 for
Waldenstrom’s macroglobulinemia in patients who have received two or more prior treatment
regimens. The PRIME designation was awarded based upon data from a pre-planned interim assessment
in the pivotal study and six patients from the Phase 2a. PRIME designation is accorded to
new therapies that demonstrate the potential to significantly address an unmet medical need
in clinical trials. Also, it allows companies to optimize development plans and accelerate
evaluation of medicines that may offer a major therapeutic advantage over existing treatments
or benefit patients without treatment options. |
| · | Continued
engagement with the U.S. Food and Drug Administration (FDA) providing additional regulatory
clarity on the pivotal clinical trial and planned new drug application (NDA) submission in
2024. This includes direct feedback on key sections of the NDA and input around the design
of a confirmatory study to support the accelerated approval strategy. |
| · | Expanded
the company’s global intellectual property portfolio with the addition of four patent
grants. The patents, which are valid across key global regions of Europe, Australia, and
Canada, cover iopofosine I 131 and the company’s proprietary Phospholipid Drug ConjugateTM
(PDC) delivery platform. |
| · | Enhanced
the company’s commercial leadership team with the appointment of two new seasoned executives,
William Yoon as vice president, medical affairs and Aaditya Nanduri as vice president, business
strategy and analytics. |
“We
continue to collect and evaluate patient data from our pivotal trial and expect to announce top-line data the week of January 8,
2024. We view this data announcement as a potentially transformational event for Cellectar and as such merits optimal market and
industry awareness, which the JP Morgan conference provides. As we prepare to announce trial data, we continue to work with the
FDA and progress the NDA submission while advancing our commercialization readiness,” said James Caruso, president and CEO of Cellectar.
“With the recent financing providing up to $102.9 million in funding, we believe the company is well positioned for success with
a clearly differentiated lead asset poised to establish a new standard of care for patients with relapsed or refractory WM.”
Preliminary Third Quarter 2023 Financial Highlights
| · | Cash
and Cash Equivalents: As of September 30, 2023, the company had cash and cash
equivalents of $19.0 million, compared to $19.9 million as of December 31, 2022. During
the third quarter, the company entered into a securities purchase agreement with certain
institutional investors for a private placement financing that is expected to result in gross
proceeds of up to $102.9 million, based upon achievement of certain milestones. Current cash
includes an initial funding of $22.2 million from the transaction, net of commissions and
fees. The company believes its cash on hand is adequate to fund budgeted operations into
the second quarter of 2024. |
| · | Research
and Development Expense: R&D expense for the three months ended September 30,
2023 was approximately $7.3 million, compared to approximately $5.4 million for the three
months ended September 30, 2022. The overall increase in research and development expense
was primarily a result of an increase in WM pivotal trial patient enrollment and expansion
of the central nervous system lymphoma cohort of the company’s Phase 2a basket trial
in blood-borne malignancies as well as initiating its pediatric study in high-grade gliomas. |
| · | General
and Administrative Expense: G&A expense for the three months ended September 30,
2023, was $2.1 million, compared to $2.4 million for the same period in 2022. The overall
decrease in G&A costs was primarily driven by reduced professional fees. |
Conference Call & Webcast Details
Cellectar
management will host a conference call for investors today, November 2, 2023, beginning at 8:30 am Eastern Time to discuss these
results and answer questions. Stockholders and other interested parties may participate in the conference call by dialing 1-888-886-7786
(in the U.S.) or 1-416-764-8658 (outside the U.S.). The call will be available via webcast by clicking HERE or on the Events
page of the company’s website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical
biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and
through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug
Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy
and better safety as a result of fewer off-target effects.
The company’s product pipeline includes
lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical
PDC chemotherapeutic programs and multiple partnered PDC assets.
For
more information, please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking
and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.
Forward-Looking Statement Disclaimer
This news release contains forward-looking statements.
You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate,"
"intend," "could," "estimate," "continue," "plans," or their negatives or cognates.
These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual
future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations
as to such future outcomes including our expectations regarding the WM CLOVER-WaM pivotal trial. Drug discovery and development involve
a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability
to raise additional capital, uncertainties related to the disruptions at our sole source supplier of iopofosine, the ability to attract
and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, patient
enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability to maintain orphan
drug designation in the United States for iopofosine, the volatile market for priority review vouchers, our pharmaceutical collaborators'
ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and
third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports
filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2022, and our Form 10-Q
for the quarter ended June 30, 2023. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation
to update any such forward-looking statements.
Contacts
INVESTORS:
Monique
Kosse
LifeSci Advisors
212-915-3820
monique@lifesciadvisors.com
MEDIA:
Claire LaCagnina
Bliss Bio Health
315-765-1462
clacagnina@blissbiohealth.com
v3.23.3
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Cellectar Biosciences (NASDAQ:CLRB)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Cellectar Biosciences (NASDAQ:CLRB)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024